Literature DB >> 15292070

Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening.

Yijun Li1, C Ronald Scott, Nestor A Chamoles, Ahmad Ghavami, B Mario Pinto, Frantisek Turecek, Michael H Gelb.   

Abstract

BACKGROUND: Newborn screening for deficiency in the lysosomal enzymes that cause Fabry, Gaucher, Krabbe, Niemann-Pick A/B, and Pompe diseases is warranted because treatment for these syndromes is now available or anticipated in the near feature. We describe a multiplex screening method for all five lysosomal enzymes that uses newborn-screening cards containing dried blood spots as the enzyme source.
METHODS: We used a cassette of substrates and internal standards to directly quantify the enzymatic activities, and tandem mass spectrometry for enzymatic product detection. Rehydrated dried blood spots were incubated with the enzyme substrates. We used liquid-liquid extraction followed by solid-phase extraction with silica gel to remove buffer components. Acarbose served as inhibitor of an interfering acid alpha-glucosidase present in neutrophils, which allowed the lysosomal enzyme implicated in Pompe disease to be selectively analyzed.
RESULTS: We analyzed dried blood spots from 5 patients with Gaucher, 5 with Niemann-Pick A/B, 11 with Pompe, 5 with Fabry, and 12 with Krabbe disease, and in all cases the enzyme activities were below the minimum activities measured in a collection of heterozygous carriers and healthy noncarrier individuals. The enzyme activities measured in 5-9 heterozygous carriers were approximately one-half those measured with 15-32 healthy individuals, but there was partial overlap of each condition between the data sets for carriers and healthy individuals.
CONCLUSION: For all five diseases, the affected individuals were detected. The assay can be readily automated, and the anticipated reagent and supply costs are well within the budget limits of newborn-screening centers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292070      PMCID: PMC3428798          DOI: 10.1373/clinchem.2004.035907

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  26 in total

1.  Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation.

Authors:  M G Ausems; J H Wokke; A J Reuser; O P van Diggelen
Journal:  Neurology       Date:  2001-11-27       Impact factor: 9.910

2.  Fabry disease: enzymatic diagnosis in dried blood spots on filter paper.

Authors:  N A Chamoles; M Blanco; D Gaggioli
Journal:  Clin Chim Acta       Date:  2001-06       Impact factor: 3.786

3.  Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for Krabbe disease.

Authors:  Yijun Li; Knut Brockmann; Frantisek Turecek; C Ronald Scott; Michael H Gelb
Journal:  Clin Chem       Date:  2004-03       Impact factor: 8.327

Review 4.  New prospects for the treatment of lysosomal storage diseases.

Authors:  Raphael Schiffmann; Roscoe O Brady
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Diagnosis of Pompe's disease using leukocyte preparations. Kinetic and immunological studies of 1,4-alpha-glucosidase in human fetal and adult tissues and cultured cells.

Authors:  Y S Shin; W Endres; J Unterreithmeier; M Rieth; J Schaub
Journal:  Clin Chim Acta       Date:  1985-05-15       Impact factor: 3.786

6.  Niemann-Pick disease type A and B are clinically but also enzymatically heterogeneous: pitfall in the laboratory diagnosis of sphingomyelinase deficiency associated with the mutation Q292 K.

Authors:  K Harzer; A Rolfs; P Bauer; M Zschiesche; E Mengel; J Backes; B Kustermann-Kuhn; G Bruchelt; O P van Diggelen; H Mayrhofer; I Krägeloh-Mann
Journal:  Neuropediatrics       Date:  2003-12       Impact factor: 1.947

7.  Tris discriminates between the different alpha-glucosidase activities from extracts of human neutrophils.

Authors:  M A Ortiz de Apodaca; E Fernandez; G de la Fuente
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

8.  Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications.

Authors:  Andreas Schulze; Martin Lindner; Dirk Kohlmüller; Katharina Olgemöller; Ertan Mayatepek; Georg F Hoffmann
Journal:  Pediatrics       Date:  2003-06       Impact factor: 7.124

9.  Screening newborns for inborn errors of metabolism by tandem mass spectrometry.

Authors:  Bridget Wilcken; Veronica Wiley; Judith Hammond; Kevin Carpenter
Journal:  N Engl J Med       Date:  2003-06-05       Impact factor: 91.245

10.  Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.

Authors:  Léon P F Winkel; Joep H J Kamphoven; Hannerieke J M P van den Hout; Lies A Severijnen; Pieter A van Doorn; Arnold J J Reuser; Ans T van der Ploeg
Journal:  Muscle Nerve       Date:  2003-06       Impact factor: 3.217

View more
  94 in total

Review 1.  Newborn screening for neuropathic lysosomal storage disorders.

Authors:  Wuh-Liang Hwu; Yin-Hsiu Chien; Ni-Chung Lee
Journal:  J Inherit Metab Dis       Date:  2010-06-08       Impact factor: 4.982

2.  New substrates and enzyme assays for the detection of mucopolysaccharidosis III (Sanfilippo Syndrome) types A, B, C, and D by tandem mass spectrometry.

Authors:  Brian J Wolfe; Farideh Ghomashchi; Tim Kim; Cynthia A Abam; Martin Sadilek; Rhona Jack; Jerry N Thompson; C Ronald Scott; Michael H Gelb; Frantisek Turecek
Journal:  Bioconjug Chem       Date:  2012-03-09       Impact factor: 4.774

3.  Feasibility of using cryopreserved lymphoblastoid cells to diagnose some lysosomal storage diseases.

Authors:  A S de Mello; F Provin; K Michelin-Tireli; M V Camelier; J C Coelho
Journal:  Cell Prolif       Date:  2010-04       Impact factor: 6.831

4.  Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis II (Hunter Syndrome).

Authors:  Brian J Wolfe; Sophie Blanchard; Martin Sadilek; C Ronald Scott; Frantisek Turecek; Michael H Gelb
Journal:  Anal Chem       Date:  2010-12-30       Impact factor: 6.986

5.  Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis IVA.

Authors:  Tanvir Khaliq; Martin Sadilek; C Ronald Scott; Frantisek Turecek; Michael H Gelb
Journal:  Clin Chem       Date:  2010-10-28       Impact factor: 8.327

6.  Neonatal screening: from the 'Guthrie age' to the 'genetic age'.

Authors:  Jean-Louis Dhondt
Journal:  J Inherit Metab Dis       Date:  2007-05-12       Impact factor: 4.982

7.  Enzyme analysis for Pompe disease in leukocytes; superior results with natural substrate compared with artificial substrates.

Authors:  O P van Diggelen; L F Oemardien; N A M E van der Beek; M A Kroos; H K Wind; Y V Voznyi; D Burke; M Jackson; B G Winchester; A J J Reuser
Journal:  J Inherit Metab Dis       Date:  2009-04-19       Impact factor: 4.982

Review 8.  Newborn screening for Krabbe's disease.

Authors:  Joseph J Orsini; Carlos A Saavedra-Matiz; Michael H Gelb; Michele Caggana
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

9.  Liquid Chromatography-Tandem Mass Spectrometry Assay of Leukocyte Acid α-Glucosidase for Post-Newborn Screening Evaluation of Pompe Disease.

Authors:  Na Lin; Jingyu Huang; Sara Violante; Joseph J Orsini; Michele Caggana; Erin E Hughes; Colleen Stevens; Lisa DiAntonio; Hsuan Chieh Liao; Xinying Hong; Farideh Ghomashchi; Arun Babu Kumar; Hui Zhou; Ruth Kornreich; Melissa Wasserstein; Michael H Gelb; Chunli Yu
Journal:  Clin Chem       Date:  2017-02-14       Impact factor: 8.327

Review 10.  Contribution of tandem mass spectrometry to the diagnosis of lysosomal storage disorders.

Authors:  Monique Piraud; Magali Pettazzoni; Pamela Lavoie; Séverine Ruet; Cécile Pagan; David Cheillan; Philippe Latour; Christine Vianey-Saban; Christiane Auray-Blais; Roseline Froissart
Journal:  J Inherit Metab Dis       Date:  2018-03-19       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.